Zacks Investment Research upgraded shares of Pieris Pharmaceuticals (NASDAQ:PIRS) from a hold rating to a buy rating in a report published on Saturday morning, Zacks.com reports. They currently have $3.75 price target on the biotechnology company’s stock.

According to Zacks, “Pieris Pharmaceuticals, Inc. is a biopharmaceutical company. The Company’s drug technology consists of Anticalin(R) to treat cancer, severe asthma, anemia and other medical conditions. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany. “

A number of other equities research analysts also recently commented on the company. ValuEngine downgraded Pieris Pharmaceuticals from a buy rating to a hold rating in a research report on Thursday, April 11th. HC Wainwright reaffirmed a buy rating and issued a $5.00 price objective on shares of Pieris Pharmaceuticals in a research report on Tuesday, March 19th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus target price of $4.38.

NASDAQ PIRS opened at $3.11 on Friday. Pieris Pharmaceuticals has a fifty-two week low of $2.39 and a fifty-two week high of $6.94. The firm has a market capitalization of $166.62 million, a PE ratio of -6.22 and a beta of 1.88.

Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings data on Monday, March 18th. The biotechnology company reported ($0.21) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.05). The business had revenue of $4.91 million during the quarter, compared to analysts’ expectations of $6.92 million. Pieris Pharmaceuticals had a negative net margin of 91.93% and a negative return on equity of 54.54%. Equities research analysts anticipate that Pieris Pharmaceuticals will post -0.81 EPS for the current year.

Several large investors have recently made changes to their positions in the company. Deutsche Bank AG grew its position in shares of Pieris Pharmaceuticals by 41.8% in the fourth quarter. Deutsche Bank AG now owns 190,266 shares of the biotechnology company’s stock valued at $505,000 after purchasing an additional 56,072 shares during the period. American Century Companies Inc. grew its position in shares of Pieris Pharmaceuticals by 37.5% in the fourth quarter. American Century Companies Inc. now owns 650,725 shares of the biotechnology company’s stock valued at $1,731,000 after purchasing an additional 177,569 shares during the period. Dimensional Fund Advisors LP purchased a new stake in shares of Pieris Pharmaceuticals in the fourth quarter valued at $374,000. 683 Capital Management LLC purchased a new stake in shares of Pieris Pharmaceuticals in the fourth quarter valued at $400,000. Finally, RBF Capital LLC purchased a new stake in shares of Pieris Pharmaceuticals in the fourth quarter valued at $747,000. 70.73% of the stock is owned by institutional investors and hedge funds.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

Featured Article: Gross Domestic Product (GDP)

Get a free copy of the Zacks research report on Pieris Pharmaceuticals (PIRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.